PHLI PacificHealth Laboratories Inc (CE)

PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading sports nutrition company, today reported its financial results for the quarter and six months ended June 30, 2011.

Second Quarter & First Half 2011 vs. 2010 Financial Results Revenues were $2,245,226 for the second quarter and $3,976,837 for the first six months of 2011 compared to $2,554,306 and $4,204,571, respectively, for the same periods in 2010. Net income for the second quarter was $91,769, or $0.00 per diluted share, and $118,999, or $0.01 per diluted share, for the first six months of 2011 compared to net income of $136,725, or $0.01 per diluted share, and a net loss of ($132,505), or ($0.01) per diluted share, for the same periods in 2010. General and administrative expenses decreased $222,953, or 30%, to $511,490 in the second quarter and $460,119, or 30%, to $1,048,474 for the first six months of 2011 compared to the same periods in 2010 primarily as a result of a reduction in personnel and personnel related expenses.

At June 30, 2011, the Company had cash, cash equivalents, and other short-term investments of $1,361,515 compared to $284,165 at December 31, 2010 primarily due to the two private placements completed in 2011.

Fred Duffner, President and CEO of PacificHealth Laboratories, said, "Revenues for the second quarter are not reflective of the progress we have made in 2011. The 5% decline in overall year to date revenues was primarily a result of a change in one of our top customers' inventory and promotional patterns. Last year they front loaded their promotions in the first half of the year and in 2011 they are spreading their promotions throughout the year. This plus the loss of sales of the discontinued FORZE™ products were the major contributors to the revenue declines during the second quarter and year to date."

Mr. Duffner added, "During the quarter we launched our new advertising campaign supporting all of our core brands as well as our new products ACCEL RECOVER™ bar and 2ND SURGE® energy gel in leading endurance magazines. Both ACCEL RECOVER and 2ND SURGE are now distributed in over 400 sports specialty retail outlets and major web sites including Performance and Road Runner stores. Starting in July the new brands were being sold in the top 1000 GNC stores. Ecommerce continues to be a strong growth area for us. To support this growth, we hired an e-commerce web manager, re-launched our website, and implemented a number of initiatives on Facebook and Twitter. We are already seeing results in terms of Internet sales. As a company, we are challenged to maintain profits in the face of increased cost of goods, particularly protein and packaging. Costs of goods for the quarter were up 3.4 percent and 2.2 percent year to date. This increase impacted second quarter profits by approximately $76,000 and $88,000 year to date."

Mr. Duffner concluded, "We have made the fundamental changes in our business needed to regain our leadership position in endurance sports nutrition. Our balance sheet is strong and I am confident that our continued investment in new products, e-commerce, advertising and promotion will drive future growth and profits."

About PacificHealth Laboratories. Inc. PacificHealth Laboratories, Inc. (OTCQB: PHLI), a leading nutrition technology company, has been a pioneer in discovering, developing and commercializing patented, protein-based nutritional products that stimulate specific peptides involved in appetite regulation and that activate biochemical pathways involved in muscle performance and growth. PHLI's principal areas of focus include sports performance and weight loss. To learn more, visit www.pacifichealthlabs.com.

Notice: This news release and oral statements made from time to time by Company representatives concerning the same subject matter may contain so-called "forward-looking statements." These statements can be identified by introductory words such as "expects," "plans," "will," "estimates," "forecasts," "projects" or words of similar meaning and by the fact they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing new products and their potential. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known, such general economic conditions, consumer product acceptance and competitive products, and others of which are not. No forward-looking statements are a guarantee of future results or events, and one should avoid placing undue reliance on such statements.

SELECTED FINANCIAL DATA:

                      PACIFICHEALTH LABORATORIES, INC.
                          STATEMENTS OF OPERATIONS
         FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2011 AND 2010
                                (UNAUDITED)

                               Three Months               Six Months
                              Ended June 30,            Ended June 30,
                             2011         2010         2011         2010
                         -----------  -----------  -----------  -----------
Revenues:
  Net product sales      $ 2,245,226  $ 2,554,306  $ 3,976,837  $ 4,204,571

Cost of goods sold         1,250,510    1,336,291    2,211,502    2,245,670
                         -----------  -----------  -----------  -----------

Gross profit                 994,716    1,218,015    1,765,335    1,958,901
                         -----------  -----------  -----------  -----------

Operating expenses:
  Sales and marketing        378,612      349,262      569,043      584,347
  General and
   administrative
   (Includes related
   party consulting of
   $48,000, $0, $91,000
   and $0, respectively)     511,490      734,443    1,048,474    1,508,593
  Research and
   development                 9,978            -       24,795            -
                         -----------  -----------  -----------  -----------
                             900,080    1,083,705    1,642,312    2,092,940
                         -----------  -----------  -----------  -----------

Income (loss) before
 other (expense) income
 and provision for
 income taxes                 94,636      134,310      123,023     (134,039)
                         -----------  -----------  -----------  -----------

Other (expense) income:
  Other income                     -        4,000        2,100        4,000
  Interest income                127          277          279          505
  Interest expense            (2,994)      (1,862)      (6,403)      (2,971)
                         -----------  -----------  -----------  -----------
                              (2,867)       2,415       (4,024)       1,534
                         -----------  -----------  -----------  -----------

Income (loss) before
 provision for income
 taxes                        91,769      136,725      118,999     (132,505)

Provision for income
 taxes                             -            -            -            -
                         -----------  -----------  -----------  -----------

Net income (loss)        $    91,769  $   136,725  $   118,999  $  (132,505)
                         ===========  ===========  ===========  ===========

Basic income (loss) per
 share                   $      0.00  $      0.01  $      0.01  $     (0.01)
                         ===========  ===========  ===========  ===========

Diluted income (loss)
 per share               $      0.00  $      0.01  $      0.01  $     (0.01)
                         ===========  ===========  ===========  ===========

Weighted average common
 shares - basic           19,723,499   16,039,606   18,202,826   15,862,791
                         ===========  ===========  ===========  ===========

Weighted average common
 shares - diluted         19,929,921   16,039,606   18,390,201   15,862,791
                         ===========  ===========  ===========  ===========

                      PACIFICHEALTH LABORATORIES, INC.
                               BALANCE SHEETS
                                (UNAUDITED)

                                   ASSETS
                                                June 30,      December 31,
                                                  2011            2010
                                             --------------  --------------
Current assets:
  Cash and cash equivalents                  $    1,286,515  $      134,165
  Other short-term investments                       75,000         150,000
  Accounts receivable, net                          981,897         416,722
  Inventories, net                                1,060,138         596,317
  Prepaid expenses                                  173,522          64,780
                                             --------------  --------------
    Total current assets                          3,577,072       1,361,984

Property and equipment, net                          31,421          52,531

Deposits                                             10,895          10,895
                                             --------------  --------------

      Total assets                           $    3,619,388  $    1,425,410
                                             ==============  ==============

                    LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Line of credit                             $       37,500  $       75,000
  Notes payable                                      58,761          20,670
  Accounts payable and accrued expenses
   (Includes related party of $91,000 and
   $11,000, respectively)                         1,645,320         713,184
  Deferred revenue                                   75,286          60,836
                                             --------------  --------------
    Total current liabilities                     1,816,867         869,690
                                             --------------  --------------

Stockholders' equity:
  Common stock, $.0025 par value; authorized
   50,000,000 shares; issued and
   outstanding: 20,865,257 and 16,485,257
   shares, respectively                              52,163          41,213
  Additional paid-in capital                     21,279,821      20,162,969
  Accumulated deficit                           (19,529,463)    (19,648,462)
                                             --------------  --------------

                                                  1,802,521         555,720
                                             --------------  --------------

      Total liabilities and stockholders'
       equity                                $    3,619,388  $    1,425,410
                                             ==============  ==============

Contact: Stephen Kuchen CFO 732-739-2900, x603 Email Contact